相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K) Differential interactions with the regulatory subunit p85 and with RAS
Li Zhao et al.
CELL CYCLE (2010)
The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status
Anna M. Dahlin et al.
CLINICAL CANCER RESEARCH (2010)
Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer
Joan N. Kyula et al.
CLINICAL CANCER RESEARCH (2010)
Clinical trials for predictive medicine: new challenges and paradigms
Richard Simon
CLINICAL TRIALS (2010)
Plasmacytoma of the Testis in a Patient With Previous Multiple Myeloma: Is the Testis a Sanctuary Site?
Shilo Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin
Michael J. O'Connell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Impact of Gene Expression-Based Classification for Neuroblastoma
Andre Oberthuer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. J. Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study
Ruth Ladenstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
S. J. Cohen et al.
ANNALS OF ONCOLOGY (2009)
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
Microsatellite Instability, MLH1 Promoter Methylation, and BRAF Mutation Analysis in Sporadic Colorectal Cancers of Different Ethnic Groups in Israel
Alex Vilkin et al.
CANCER (2009)
Sorafenib Inhibits Non-Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells
Ken Takezawa et al.
CANCER RESEARCH (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Claudia Scholl et al.
CELL (2009)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2009)
Distinct BRAF (V600E) and KRAS Mutations in High Microsatellite Instability Sporadic Colorectal Cancer in African Americans
Krishan Kumar et al.
CLINICAL CANCER RESEARCH (2009)
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Sumithra J. Mandrekar et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Bart Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
Azim M. Mohamedali et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Metabolic Profiling of Human Colorectal Cancer Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HR-MAS NMR) Spectroscopy and Gas Chromatography Mass Spectrometry (GC/MS)
Eric Chun Yong Chan et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations
Matthias Holdhoff et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Herbert I. Hurwitz et al.
ONCOLOGIST (2009)
Circulating tumor cells in colorectal cancer:: correlation with clinical and pathological variables
J. Sastre et al.
ANNALS OF ONCOLOGY (2008)
Approaches to working in high-dimensional data spaces: gene expression microarrays
Y. Wang et al.
BRITISH JOURNAL OF CANCER (2008)
Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
Ludovic Barault et al.
CANCER RESEARCH (2008)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line Models
Wendy L. Allen et al.
CLINICAL CANCER RESEARCH (2008)
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
Amy J. French et al.
CLINICAL CANCER RESEARCH (2008)
The Use of Genomics in Clinical Trial Design
Richard Simon
CLINICAL CANCER RESEARCH (2008)
Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone
Daniel J. Freeman et al.
CLINICAL COLORECTAL CANCER (2008)
RNA expression analysis from formalin fixed paraffin embedded tissues
Susan M. Farragher et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
The difficult patient
Carrie A. Thompson
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary
Hugo M. Horlings et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover
Carsten Denkert et al.
MOLECULAR CANCER (2008)
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
Kevin M. Haigis et al.
NATURE GENETICS (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Sunitha Nagrath et al.
NATURE (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Sue-Jane Wang et al.
PHARMACEUTICAL STATISTICS (2007)
Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues
Jun Chen et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
Maguy Del Rio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Human epidermal growth factor receptor 2 testing recommendation - In reply
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Converting a breast cancer microarray signature into a high-throughput diagnostic test
Annuska M. Glas et al.
BMC GENOMICS (2006)
Stage II colon cancer prognosis prediction by tumor gene expression profiling
Alain Barrier et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
Marc Buyse et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
Leming Shi et al.
NATURE BIOTECHNOLOGY (2006)
Use of genomic signatures in therapeutics development in oncology and other diseases
R. Simon et al.
PHARMACOGENOMICS JOURNAL (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers
M Gaasenbeek et al.
CANCER RESEARCH (2006)
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer
J Boyer et al.
CANCER RESEARCH (2006)
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild et al.
NATURE (2006)
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status
Wei Qi Li et al.
MOLECULAR CANCER (2006)
Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays
EH Lips et al.
CANCER RESEARCH (2005)
Roadmap for developing and validating therapeutically relevant genomic classifiers
R Simon
JOURNAL OF CLINICAL ONCOLOGY (2005)
Colon cancer prognosis prediction by gene expression profiling
A Barrier et al.
ONCOGENE (2005)
Molecular staging for survival prediction of colorectal cancer patients
S Eschrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
On the efficiency of targeted clinical trials
A Maitournam et al.
STATISTICS IN MEDICINE (2005)
Clinical trial designs for prospective validation of biomarkers
SJ Mandrekar et al.
AMERICAN JOURNAL OF PHARMACOGENOMICS (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
AB Benson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
T Kambara et al.
GUT (2004)
Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells
D Arango et al.
BRITISH JOURNAL OF CANCER (2004)
Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays
M Bibikova et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Evaluating the efficiency of targeted designs for randomized clinical trials
R Simon et al.
CLINICAL CANCER RESEARCH (2004)
Gene expression profiles and molecular markers to predict recurrence of dukes' B colon cancer
YX Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gene expression profiles of primary breast tumors maintained in distant metastases
B Weigelt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prognostic significance of microsatellite instability and ki-ras mutation type in stage II colorectal cancer
C Wang et al.
ONCOLOGY (2003)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability
N Hawkins et al.
GASTROENTEROLOGY (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
H Elsaleh et al.
LANCET (2000)
分享论文
